Tim Schofield Appointed as New Chair of the IABS Biotherapeutics Committee
It is a pleasure to announce the appointment of Timothy (Tim) Schofield as Chairman of the IABS Biotherapeutics Committee. On December 9, 2017, the Executive Committee unanimously endorsed Tim to succeed Anthony Mire-Sluis.
Tim is a Senior Advisor in Global Vaccines Technical R&D at GlaxoSmithKline. Prior to joining GSK Tim worked at MedImmune as Senior Fellow in Analytical Biotechnology, Arlenda, Inc. as Managing Director and Head of Nonclinical Statistics, at GSK in US Regulatory Affairs, and at the Merck Research Laboratories heading the Nonclinical Statistics unit, supporting research, development and manufacture of Merck pharmaceuticals, biologics and vaccines. Tim received a Bachelor of Science degree in Mathematics from Lafayette College, and a Master of Arts degree in Statistics and Operations Research in 1976 from the Wharton School of the University of Pennsylvania. Tim is a member of the USP Statistics Expert Committee and has participated in industry initiatives related to Quality by Design, analytical method development and validation, stability and specifications. In addition to serving as the Chairman of the IABS Biotherapeutics Committee, he is a member of the International Consortium for Innovation & Quality (IQ) Biologics Leadership Group. Tim brings a wealth of experience in the biological standardization arena and a tremendous energy as Committee Chair. IABS is lucky to have him join our three other Scientific Committee Chairs in advancing the mission of IABS. Note too that there are vacancies on the Biotherapeutics Committee that Tim will be filling in the near future.
Joris Vandeputte, President IABS